Investor profile
RA Capital Management has backed 10 European tech companies across 10 funding rounds between 2018 and 2025, joining rounds totalling €1.6B. Most active in Healthtech. Data as of 7 Aug 2026.
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
| Company | Country | Rounds | Total € |
|---|---|---|---|
| Bicycle Therapeutics | UK | 1 | €512M |
| Verdiva Bio | UK | 1 | €399M |
| Artios | UK | 1 | €198M |
| Hemab Therapeutics | Denmark | 1 | €127M |
| Pepgen | UK |
| Company | Stage | Amount | Date |
|---|---|---|---|
| Bicycle Therapeutics | Other | €512M | 2024-05 |
| Verdiva Bio | Series A | €399M | 2025-01 |
| Hemab Therapeutics | Series B | €127M | 2023-02 |
| Artios |
| 1 |
| €95M |
| T-knife | Germany | 1 | €93M |
| Ambagon Therapeutics | Netherlands | 1 | €75M |
| Alchemab Therapeutics | UK | 1 | €69M |
| Nucleix | Israel | 1 | €47M |
| Whiteswell | Ireland | 1 | €26M |
| Series D+ |
| €99M |
| 2025-11 |
| Artios | Series D+ | €99M | 2025-11 |
| Pepgen | Other | €95M | 2021-08 |
| T-knife | Series B | €93M | 2021-08 |
| Ambagon Therapeutics | Series A | €75M | 2022-01 |
| Alchemab Therapeutics | Series A | €69M | 2021-04 |
| Nucleix | Other | €47M | 2021-04 |
